https://scholars.lib.ntu.edu.tw/handle/123456789/543439
標題: | A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data | 作者: | Chen L.-T. Satoh T. Ryu M.-H. Chao Y. Kato K. Chung H.C. Chen J.-S. Muro K. Kang W.K. KUN-HUEI YEH Yoshikawa T. Oh S.C. Bai L.-Y. Tamura T. Lee K.-W. Hamamoto Y. Kim J.G. Chin K. Oh D.-Y. Minashi K. Cho J.Y. Tsuda M. Sameshima H. Kang Y.-K. Boku N. |
關鍵字: | Gastric cancer; Gastroesophageal junction cancer; Long-term; Nivolumab; Placebo | 公開日期: | 2020 | 出版社: | Springer | 卷: | 23 | 期: | 3 | 起(迄)頁: | 510-519 | 來源出版物: | Gastric Cancer | 摘要: | Background: Nivolumab showed improvement in overall survival (OS) in ATTRACTION-2, the first phase 3 study in patients with gastric/gastroesophageal junction (G/GEJ) cancer treated with ? 2 chemotherapy regimens. The 2-year follow-up results of ATTRACTION-2 are presented herein. Methods: ATTRACTION-2 was a randomized, double-blind, placebo-controlled, phase 3 trial (49 sites; Japan, South Korea, and Taiwan). The median (min–max) follow-up period was 27.3 (24.1–36.3)?months. The primary endpoint was OS. A subanalysis of OS was performed based on best overall response and tumor-programmed death ligand-1 (PD-L1) expression status. Results: Overall, 493 of 601 screened patients were randomized (2:1) to receive nivolumab (330) or placebo (163). OS (median [95% confidence interval; CI]) was significantly longer in the nivolumab group (5.26 [4.60–6.37] vs 4.14 [3.42–4.86]?months in placebo group) at the 2-year follow-up (hazard ratio [95% CI], 0.62 [0.51–0.76]; P < 0.0001). A higher OS rate was observed in the nivolumab vs placebo group at 1 (27.3% vs 11.6%) and 2?years (10.6% vs 3.2%). The OS benefit was observed regardless of tumor PD-L1 expression. Among patients with a complete or partial response (CR or PR) in the nivolumab group, the median OS (95% CI) was 26.6 (21.65—not applicable)?months; the OS rates at 1 and 2?years were 87.1% and 61.3%, respectively. No new safety signals were identified. Conclusions: Nivolumab treatment resulted in clinically meaningful long-term improvements in OS in patients with previously treated G/GEJ cancer. The long-term survival benefit of nivolumab was most evident in patients with a CR or PR. ? 2019, The Author(s). |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85077072708&doi=10.1007%2fs10120-019-01034-7&partnerID=40&md5=49ecd6a7c31d819d6fad1024dd7f4746 https://scholars.lib.ntu.edu.tw/handle/123456789/543439 |
ISSN: | 1436-3291 | DOI: | 10.1007/s10120-019-01034-7 | SDG/關鍵字: | nivolumab; placebo; programmed death 1 ligand 1; immunological antineoplastic agent; nivolumab; adult; advanced cancer; aged; Article; controlled study; disease exacerbation; double blind procedure; drug efficacy; drug safety; drug withdrawal; esophagus cancer; female; follow up; gastroesophageal junction; human; human tissue; interstitial lung disease; Japan; maculopapular rash; major clinical study; male; overall survival; phase 3 clinical trial; pneumonia; priority journal; progression free survival; randomized controlled trial; South Korea; stomach cancer; Taiwan; treatment duration; treatment response; tumor growth; clinical trial; drug effect; esophagus tumor; gastroesophageal junction; middle aged; multicenter study; pathology; prognosis; salvage therapy; stomach tumor; survival rate; Aged; Antineoplastic Agents, Immunological; Double-Blind Method; Esophageal Neoplasms; Esophagogastric Junction; Female; Follow-Up Studies; Humans; Japan; Male; Middle Aged; Nivolumab; Prognosis; Republic of Korea; Salvage Therapy; Stomach Neoplasms; Survival Rate; Taiwan |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。